Advocate

imidacloprid / moxidectin

Opinion

On 20 June 2019,the Committee for Medicinal Products for Veterinary Use (CVMP)adopted a positive opinion1, recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product Advocate. The marketing authorisation holder for this veterinary medicinal product is Bayer Animal Health GmbH.

Advocate is currently authorised as spot-on solution for cats, ferrets and dogs. The variation concerns the addition of new therapeutic indications in cats: the prevention and treatment of Aelurostrongylus abstrusus and the treatment of Thelazia callipaeda; also, the product information is amended with regard to pharmacological properties of moxidectin in cats.

Detailed conditions for the use of this product are described in the updated summary of product characteristics (SPC), for which an updated version reflecting the changes will be published in the revised European public assessment report (EPAR) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.


1 Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Key facts

Name
Advocate
Agency product number
EMEA/V/C/000076
International non-proprietary name (INN) or common name
  • imidacloprid / moxidectin
Species
Ferrets
Dogs
Cats
Active substance
  • imidacloprid
  • moxidectin
Date opinion adopted
20/06/2019
Company name
Bayer Animal Health GmbH
Status
Positive
Application type
Post-authorisation

Related content

How useful was this page?

Add your rating